{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "TWD", "marketState": "POSTPOST", "regularMarketChangePercent": -0.9772024, "regularMarketPrice": 30.4, "exchange": "TWO", "shortName": "GLYCONEX INCORPORATION", "longName": "GlycoNex Incorporation", "messageBoardId": "finmb_142686904", "exchangeTimezoneName": "Asia/Taipei", "exchangeTimezoneShortName": "CST", "gmtOffSetMilliseconds": 28800000, "market": "tw_market", "esgPopulated": false, "regularMarketTime": 1684128622, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.21, "sharesOutstanding": 107098000, "bookValue": 13.498, "fiftyDayAverage": 31.809, "fiftyDayAverageChange": -1.4090004, "fiftyDayAverageChangePercent": -0.044295654, "twoHundredDayAverage": 31.83475, "twoHundredDayAverageChange": -1.4347496, "twoHundredDayAverageChangePercent": -0.045068663, "marketCap": 3255779072, "priceToBook": 2.2521853, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1340154000000, "priceHint": 2, "regularMarketChange": -0.30000114, "regularMarketDayHigh": 31.3, "regularMarketDayRange": "30.25 - 31.3", "regularMarketDayLow": 30.25, "regularMarketVolume": 576602, "regularMarketPreviousClose": 30.7, "bid": 30.4, "ask": 30.5, "fullExchangeName": "Taipei Exchange", "financialCurrency": "TWD", "regularMarketOpen": 30.9, "averageDailyVolume3Month": 1431964, "averageDailyVolume10Day": 1119500, "fiftyTwoWeekLowChange": 6.1499996, "fiftyTwoWeekLowChangePercent": 0.25360823, "fiftyTwoWeekRange": "24.25 - 46.9", "fiftyTwoWeekHighChange": -16.500002, "fiftyTwoWeekHighChangePercent": -0.3518124, "fiftyTwoWeekLow": 24.25, "fiftyTwoWeekHigh": 46.9, "symbol": "4168.TWO"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "No. 97, Xintai 5th Road", "address2": "8th Floor Sec. 1 Xizhi District", "city": "New Taipei City", "zip": "221", "country": "Taiwan", "phone": "886 2 2697 4168", "fax": "886 2 2697 1168", "website": "https://www.glyconex.com.tw", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. Its technology platform enables glycan-directed cancer therapy and analytical tools for glycosylation. The company develops GNX102, a humanized antibody for cancer; and GNX201, GNX202, GNX203, and GNX204 for various solid tumors. It also develops Denosumab, a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and Aflibercept, a vascular endothelial growth factor binding fusion protein for the treatment of ophthalmology and oncology. GlycoNex Incorporation was founded in 2001 and is based in New Taipei City, Taiwan.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Mei-Chun  Yang", "title": "Pres, CEO & Mang.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ti-Fen  Wu", "title": "Chief Financial Officer & Accounting Supervisor", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Yaohua  Lu", "title": "VP of Admin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}